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The purpose of this study was to synthesize biocompatible poly(2-hydroxyethyl aspartamide)–C16-iron oxide
(PHEA-C16-iron oxide) nanoparticles and to evaluate their efficacy as a contrast agent for magnetic resonance
imaging of lymph nodes. The PHEA-C16-iron oxide nanoparticles were synthesized by coprecipitation method.
The core size of the PHEA-C16-iron oxide nanoparticles was about 5 to 7 nm, and the overall size of the
nanoparticles was around 20, 60, and 150 nm in aqueous solution. The size of the nanoparticles was controlled by
the amount of C16. The 3.0-T MRI signal intensity of a rabbit lymph node was effectively reduced after intravenous
administration of PHEA-C16-iron oxide with the size of 20 nm. The in vitro and in vivo toxicity tests revealed the high
biocompatibility of PHEA-C16-iron oxide nanoparticles. Therefore, PHEA-C16-iron oxide nanoparticles with 20-nm size
can be potentially useful as T2-weighted MR imaging contrast agents for the detection of lymph nodes.
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Accurate diagnosis of lymph node metastasis in various
cancer patients is very important as it is one of the most
important factors for the choice of preoperative chemo-
radiotherapy, surgical treatment, and patient prognosis
[1]. Recently, magnetic resonance (MR) imaging with ul-
trasmall superparamagnetic iron oxide (USPIO) has
gained approval as a noninvasive method for the detec-
tion of lymph node metastases in several tumors [2,3].
MR provides images with excellent anatomical detail
but, at the same time, is relatively insensitive to lymph
node metastases due to the limited sensitivity of current
node size criteria in differentiating benign from malig-
nant nodes. However, the MR results can be improved
by using a superparamagnetic contrast agent such as
USPIO [4,5]. USPIO acts as a negative contrast agent,
and therefore, normal functioning lymph nodes can be* Correspondence: chocw@cnu.ac.kr; shcho@krict.re.kr
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in any medium, provided the original work is pdistinguished from lymph node metastases on the basis
of magnetic resonance signal characteristics, independ-
ent of nodal size [6-9]. USPIO nanoparticles have offered
new potential for early detection of lymph nodes and
their metastases using magnetic resonance imaging
(MRI). These nanoparticles are taken up by macro-
phages in normal lymph nodes and show signal reduc-
tion (e.g., by susceptibility-based relaxation). Because
less nanoparticle uptake is seen in metastatic nodes,
these nodes may be overlooked as a result of the min-
imal signal change in the occupying mass. Fortunately,
among various MR protocols that show the lymph
nodes, susceptibility base sequences are very sensitive to
small magnetic changes inside the nodes [10]. Some
USPIO particles (mean diameter less than 50 nm) are
used as MRI contrast agents (e.g., Sinerem®, European
Medicines Agency, Canary Wharf, London; Combidex®,
Radboud University Nijmegen Medical Centre, Nijmegen,
Netherlands; Clariscan™, Nycomed, Drammensveien,
Asker, Norway) to differentiate metastatic nodes from
lymph nodes. These USPIOs are composed of iron oxide
nanoparticles coated with polymers such as low molecular
weight dextran and polyethyleneglycol (PEG).pen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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(2-hydroxyethyl aspartamide) (PHEA) graft copolymer,
and not a block copolymer, to form biocompatible
USPIO (less than 30 nm in diameter). PHEA, which is a
poly(amino acid) derivative, was used to coat the iron
oxide (Fe3O4) nanoparticles for MRI applications. PHEA
is a synthetic polymer having a protein-like structure,
obtained by the reaction of ethanolamine with poly-
succinimide (PSI), which is prepared by thermal poly-
condensation of D,L-aspartic acid. PHEA has good
biopharmaceutical properties as drug carrier such as
high water solubility, multi-functionality, absence of
toxicity, antigenicity, immunogenicity, and low cost of
production [11-17]. Hydrophobic side chain was grafted
to the PHEA backbone to aid in good solubility of hydro-
phobic Fe3O4 nanoparticles in aqueous phases. Hexadecyl
alkyl groups permit hydrophobic interaction with ligands
on Fe3O4 nanoparticles, and hydrophobic van der Waals
interaction affords good stability in aqueous solution [18].
In this paper, we synthesized amphiphilic graft deriva-
tives of PHEA by the introduction of hydrophobic hexa-
decylamine (C16) as a linker of iron oxide. We evaluated
the feasibility of using PHEA-C16-iron oxide nanoparti-
cles as MRI contrast agent for the detection of lymph




Polysuccinimide (2,000 ~ 3,000 g/mol) was purchased
from Baypure, Bayer Chemicals AG, Leverkusen,
Germany. 1-Hexadecylamine (C16-NH2), ethanolamine,
ammonium hydroxide (NH3 content 28 % ∼ 30 %), ferrous
chloride tetrahydrate (FeCl2 · 4H2O), ferric chloride hexa-
hydrate (FeCl3 · 6H2O) were purchased from Aldrich
Chemical Company, Inc., Milwaukee, WI, USA. N,
N-dimethylformamide (DMF) was purchased from Junsei
Chemical Co., Ltd., Tokyo, Japan. Hallow fiber filter mem-
brane (dialysis with tangential flow separation module)
and peristatic pump for the purification of large amounts
of contrast agent were purchased from KD Scientific,
Holliston, MA, USA. Freeze dryer Bondiro and deep
freezer Gudero were purchased from Ilshin, Daejeon,
South Korea. Pure 18.2 MΩ cm distilled water was used
by Milli-Q, Millipore, Molsheim, France. All the other re-
agents were commercially available and used without fur-
ther purification. A commercial contrast agent, Resovist®
1.4 ml (SH U 555 A) as a control for comparison with ex-
periment was purchased from Schering Bayer AG, Berlin,
Germany.
Synthesis of PHEA-C16-iron oxide
Different amounts of C16 (3.26, 6.51, and 13.02 g) in
DMF (15, 30, and 60 ml) were added dropwise to asolution of PSI (15 g, 1.5 × 10−3 mol) in DMF (100 ml).
The mixture was stirred at 70°C under a nitrogen atmos-
phere. After 1 h, ethanolamine (7.49 ml, 0.125 mol) was
added dropwise to the reaction solution. The mixture
was stirred at room temperature for 24 h, under a nitro-
gen atmosphere. The reaction solution was precipitated
and filtered with ethyl ether for the removal of DMF and
unreacted materials. The filtered PHEA-C16 was washed
with ethyl ether and dried under vacuum at 60°C.
PHEA-C16 (1.16 g, 2 × 10
−4 mol), FeCl2 · 4H2O (0.0794 g,
4 × 10−4 mol), and FeCl3 · 6H2O (0.1584 g, 6 × 10
−4 mol)
were dissolved in distilled water (40 ml). The resulting
mixture was stirred at 80°C for 1 h under vigorous
mechanical stirring, and ammonia solution (3 ml) was
added dropwise to the reaction solution. During this
process, the initial orange color of the solution gradually
turned into a brownish black colloidal solution. The col-
loidal solution was cooled to room temperature for
10 min, and distilled water (80 ml) was added to the
brownish black colloidal solution. This solution was cen-
trifuged at 6,000 rpm for 15 min. The upper-layer solu-
tion of the unreacted polymer was removed from the
PHEA-C16-iron oxide, with the pH adjusted, and con-
centrated using hollow fiber. And, the dialyzed colloidal
solution was freeze-dried.
Characterization analysis
The results of polymerization were confirmed by 1H
NMR (300 and 500 MHz, Bruker, Billerica, MA, USA).
Dimethyl sulfoxide (DMSO, Aldrich) was used as a solv-
ent. Particle size distribution of the PHEA-C16-iron
oxide nanoparticles in the colloidal was analyzed using
an electrophoresis light scattering (ELS 8000, OTSUKA
Electronics Co., Ltd., Osaka, Japan). The size and
morphology of the PHEA-C16-iron oxide nanoparticles
were examined using a transmission electron microscope
(TEM; JEM-2010, JEOL, Tokyo, Japan). The powder
after being dissolved in ethanol was drop casted onto a
300-mesh carbon-coated copper grid, and the grid was
air-dried at room temperature before viewing under the
microscope. The magnetic properties of the PHEA-C16-iron
oxide nanoparticles were carried out at room temperature
with /H/ ≤20 kOe using Quantum Design MPMS 5 SQUID
magnetometer (San Diego, CA, USA).
In vitro MRI test
To confirm the feasibility of the PHEA-C16-iron oxide
nanoparticles as an MRI contrast agent, we first pre-
pared a ferrofluid phantom consisting of PHEA-C16-iron
oxide nanoparticles and Resovist® with Fe concentrations
varying from 9 to 1,250 μM in deionized water. Every
sample was filled into an arrangement of 2-ml tubes
without air in a plastic rack. The tubes containing the
samples were embedded in a phantom which consisted
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[19]. MRI was performed using a 3.0-T MRI system
(Intera Achieva 3.0 T, Philips Medical Systems, Philips
Co., Best, The Netherlands). The T2-weighted image of
the phantom was obtained with a turbo spin echo tech-
nique. The sequence parameters were 4,341 ms of repe-
tition time (TR), 79.4 ms of echo time (TE), 1-mm
thickness, and 256-mm field of view (FOV).
In vivo MRI test
To observe the in vivo MRI effect of lymph node, T2-
weighted MRI was performed in normal healthy New
Zealand White rabbits weighing 3.3 kg. The rabbits were
anesthetized with an injection of pentobarbital (1 M).
The PHEA-C16-iron oxide (0.45 mmol Fe, 25.13 mg Fe)
was administered into a marginal vein of the rabbit's ear
through the catheter. The T2-weighted MRI images were
obtained before administration and 20 min after admin-
istration of the PHEA-C16-iron oxide nanoparticles. The
T2-weighted MR imaging of the lymph node was per-
formed with a turbo spin echo technique. The sequence
parameters were 5,383 ms of TR, 79.4 ms of TE, 1-mm
thickness, and 112-mm FOV. The rabbit was sacrificed
immediately after MR imaging test for the confirmation
of PHEA-C16-iron oxide nanoparticles taken up by
lymph node. The specimens was fixed in 10% formalin
for 24 h and embedded in paraffin. Prussian blue stain-
ing was performed on 5-μm thick sections: the prepara-
tions were treated with a mixture of equal parts of 20%
hydrochloric acid and 10% potassium ferrocyanide solu-
tion for 20 min and counterstained with nuclear fast red
for 5 min. The principle of this method is that the ferric
iron (Fe3+) in the tissue combines with the ferrocyanide
and results in the formation of a bright blue pigment
called Prussian blue.
In vitro and in vivo toxicity tests
A single-dose intravenous toxicity study of PHEA-C16-iron
oxide in Sprague–Dawley rats
This study was carried out to evaluate the toxicity of
PHEA-C16-iron oxide in Sprague–Dawley rats (8 weeks
old, Koatech, Seoul, South Korea) after a single intraven-
ous administration. PHEA-C16-iron oxide was adminis-
tered intravenously at dose levels of 0 (vehicle control),
800, 1,200, and 1,800 mg/kg. Each group consisted of
five rats of both sexes. After the administration, the
mortality rate, clinical signs, body weights, and gross
necropsy findings were compared with those of the ve-
hicle control group. All experiments were performed at
the preclinical research center of ChemOn, Inc., a na-
tionally recognized testing laboratory recognized by
Korea Food and Drug Administration (KFDA), according
to the guidelines of GLP: the standards of toxicity study
for medicinal products (notification no. 2005–60 (October21, 2005, KFDA)) and good laboratory practice regulation
for nonclinical laboratory studies (notification no.
2005–79 (December 21, 2005, KFDA)).
Micronucleus test of PHEA-C16-iron oxide in bone marrow
cells of female ICR mice (intravenous study)
A micronucleus test of PHEA-C16-iron oxide was con-
ducted using female imprinting control region (ICR)
strain-specific pathogen-free (SPF) mice. The PHEA-C16-
iron oxide was dissolved in sterilized distilled water.
Seven-week-old female ICR mice were intravenously ad-
ministered with PHEA-C16-iron oxide for two consecutive
days at doses of 0, 125, 250, and 500 mg/kg/day. Six mice
were assigned per dose group. The positive control (cyclo-
phosphhamide∙H2O, 70 mg/kg) was given once intraperi-
toneally on the day of second administration. All animals
were sacrificed about 24 h after the second administration,
and bone marrow preparations were made.
Bacterial reverse mutation test of PHEA-C16-iron oxide
Bacterial reverse mutation test of PHEA-C16-iron oxide
was evaluated for its potential effect to induce reverse
mutation in the histidine auxotroph strains of Salmon-
ella typhimurium TA 100, TA 1535, TA 98, and TA
1537, and atryptophan auxotroph strain of Escherichia
coli WP2 uvrA. PHEA-C16-iron oxide for treatment was
dissolved in sterilized distilled water, filtered with a syr-
inge filter (pore size 0.2 μm), and serial dilutions were
made. All bacterial strains were exposed to PHEA-C16-
iron oxide in the presence and absence of exogenous
metabolic activation system. The metabolic activation
system was prepared with Aroclor 1254-induced rat liver
homogenate (S-9) and cofactor. The dose levels of the
PHEA-C16-iron oxide were 62, 185, 556, 1,667, and
5,000 μg/plate for all strains. For all strains, correspond-
ing vehicle control and positive control groups were also
included. Three plates were used per dose, and tester
strains were exposed to the PHEA-C16-iron oxide by dir-
ect plate incorporation method. The plates were incu-
bated for about 48 h after treatment, and colonies were
counted.
In vitro mammalian chromosome aberration test of
PHEA-C16-iron oxide in cultured Chinese hamster lung cells
This study was carried out to evaluate the mutagenic po-
tential of PHEA-C16-iron oxide in terms of clastogenicity
using cultured Chinese hamster lung (CHL) cells in the
presence (+S) and absence (−S) of metabolic activation
system. The metabolic activation system was prepared
with Aroclor 1254-induced rat liver homogenate and co-
factor. The PHEA-C16-iron oxide was suspended in
complete culture medium (minimum essential medium),
and serial dilutions were made for treatment. The high-
est dose for each treatment series was determined based
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The doses are 138, 275, 550, and 600 μg/ml (6 h); 10, 20,
40, and 50 μg/ml (6 h); and 10, 20, 30, 40 μg/ml (24 h)
with appropriate negative and positive controls to evalu-
ate the mutagenic potential of PHEA-C16-iron oxide in
presence (+S), absence (−S), and absence (−S) of meta-
bolic activation system, respectively.
All the experiments were performed in duplicate for
each dose. Rapidly growing cell cultures were trypsi-
nized, and three series of 25-cm2 culture flasks (Falcon,
Corning, Inc., Tewksbury MA, USA) were seeded with
6 × 104 cells, each in 5-ml medium, and incubated for 3
days before the chemical treatment. The mitotic cells of
each flask were harvested 24 h after the start of treat-
ment, and chromosome preparations were made. A hun-
dred metaphases per culture (200 metaphases per dose)
were analyzed from a selected slide in each culture.
All tests were performed according to the guidelines
of GLP: the standards of toxicity study for medicinal
products (notification no. 2005–60 (October 21, 2005,
KFDA)), good laboratory practice regulation for non-
clinical laboratory studies (notification no. 2005–79
(December 21, 2005, KFDA)), and OECD Guideline for
the Testing of Chemicals (TG 473 (1997) ‘In vitro
Mammalian Chromosomal Aberration Test’).
Results
Synthesis and characterization of PHEA-C16-iron oxide
To prepare the PHEA-C16-coated iron oxide nanoparti-
cles as a contrast agent, PHEA-C16 was synthesized by
aminolysis of PSI with ethanol amine and hexadecyla-
mine. The overall synthetic route of PHEA-C16 and
1H
NMR of PSI and PHEA-C16 are shown in Figure 1. In
PSI, the signals at 5.04 ppm were assigned to the methy-
lene proton (a) of the repeating succinimide unit, and
those at 2.5 to 3.5 ppm were assigned to methyleneFigure 1 The overall synthetic scheme of PHEA-C16 and
1H NMR specproton (b). The degree of substitution (DS) of C16 in the
grafted PHEA polymer was calculated by comparing the
integral of the CH2 peak at δ 1.3 of hexadecylamine to
the integral of the peak at δ 5.04 assigned to the protons
that belong to the PSI unit. Hexadecyl alkyl groups inter-
act with iron oxide nanoparticles through hydrophobic
van der Waals interaction, which lead to a formation of a
spherical-shaped structure [18]. Hydrophobic Fe3O4 nano-
particles were synthesized by a typical coprecipitation
method. The particle sizes were controlled by varying the
degree of substitution of the hydrophobic hexadecylamine
groups. With the increase of DS of C16, the mean particle
sizes decreased, as presented in Table 1.
Characterization analysis of iron oxide nanoparticles
Figure 2 is the TEM image and DLS data of the PHEA-
C16-iron oxide nanoparticles. The TEM image shows
that the diameter of the iron oxide core is 5 to 7 nm as
illustrated in Figure 2A. In the aqueous solution, the col-
loidal nanoparticles have a hydrodynamic diameter of
about 20, 60, and 150 nm with various amounts of
C16 by dynamic light scattering (DLS) measurements
(Figure 2B,C,D).
The hysteresis loop of the PHEA-C16-iron oxide nano-
particles shown in Figure 3 had no coercive force, showing
superparamagnetic behavior and a high magnetic moment
in a high magnetic field (generally, about 5 to about
90 emu/g of metal oxide). The saturation magnetization
of the PHEA-C16-coated iron oxide nanoparticles was
20 emu/g Fe.
In vitro MRI test
T2-weighted MRI was obtained with a 3.0-T MRI system
(Intera Achieva 3.0 T, Philips Medical Systems, Philips
Co.) for the comparison of the MR contrast effect of the
phantom made of the synthesized PHEA-C16-iron oxidetra of PSI, PHEA-C16.
Table 1 Particle size with various amounts of C16
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the synthesized PHEA-C16-iron oxide colloids and Resovist®
in the same concentration gradient in distilled water.
Figure 4B shows the signal intensity values converted by
the image analysis tool for quantitative measurement. The
results indicate that the PHEA-C16-iron oxide is slightly
better than Resovist® as a T2 negative contrast agent for
MRI.
In vivo MRI test
The PHEA-C16-iron oxide nanoparticles were injected
intravenously into a marginal vein of the rabbit's ear
through the catheter to obtain T2-weighted MRI images.
Figure 5 shows the T2-weighted MRI images before and
after the injection of the PHEA-C16-iron oxide nanopar-
ticles into a rabbit. It shows a profound negative en-
hancement of the bone marrow and lymph node afterFigure 2 TEM image and size distribution. (A) TEM image and size distr
oxide nanoparticles.the injection of the PHEA-C16-iron oxide nanoparticles.
From the results, we confirmed that the synthesized
PHEA-C16-iron oxide significantly improved the detec-
tion of the bone marrow and lymph node by MRI.
Figure 6 shows the uptake of the PHEA-C16-iron oxide
nanoparticles by the lymph node of rabbit on Prussian
blue staining 20 min after the injection of PHEA-C16-
iron oxide.
In vitro and in vivo toxicity tests
A single-dose intravenous toxicity study of PHEA-C16-iron
oxide in Sprague–Dawley rats
All male and female animals in the 1,800-mg/kg treat-
ment group were observed dead, and one dead female
animal was found in the 1,200-mg/kg treatment group.
The clinical signs included abnormalities attributable to
the PHEA-C16-iron oxide such as hematuria, loss of tail,
soft stool, reddish tear, hypothermia, inanimation, and
death. Based on the aforementioned results, following
the single-dose intravenous administration of PHEA-
C16-iron oxide in Sprague–Dawley rats, the lethal dose
50 (LD50) was 1,494 mg/kg Fe for males and 1,300
mg/kg Fe for females. A 95% confidence interval was
not calculated.ibution of (B) 20-nm, (C) 60-nm, and (D) 150-nm PHEA-C16-iron
Figure 3 Magnetization curve of the PHEA-C16-iron oxide nanoparticles with 20 nm at room temperature.
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cells of female ICR mice (intravenous study)
There was no statistically significant increase in the fre-
quencies of MNPCEs among 2,000 PCEs in any dose
level of PHEA-C16-iron oxide. The ratio of PCE to total
erythrocytes (PCE/PCE +NCE) was 0.36 in all groups
treated with PHEA-C16-iron oxide, and there was no sta-
tistically significant difference at any dose levels of
PHEA-C16-iron oxide when compared with the vehicle
controls. No mortality was observed at any of the dose
levels, and there were no abnormal clinical signs attributedFigure 4 Images of the synthesized PHEA-C16-iron oxide colloids and
acquired from T2-spin-eco-weighed MR images at different iron concentrati
of Resovist® and the PHEA-C16-iron oxide.to the administration of PHEA-C16-iron oxide. There was
no significant change in body weights as well. Therefore,
PHEA-C16-iron oxide did not induce micronucleus in the
bone marrow cells of ICR mice used in the present study.
Bacterial reverse mutation test of PHEA-C16-iron oxide
There was no microbial colony in any of the plates for
sterility check of high-dose PHEA-C16-iron oxide and
S-9 mix. The viable cell counts of tester strains were
0.71 × 109 to 1.65 × 109 CFU/ml for TA strains, and
2.31 × 109 CFU/ml for WP2 uvrA. It showed thatResovist®, and signal intensity values. (A) Phantom images
ons. (B) The T2 MR signal intensity is affected by the iron concentrations
Figure 5 T2-weighted MRI images of the PHEA-C16-iron oxide nanoparticles into a rabbit. Lymph node and bone marrow MR images of a
rabbit before (left) and after (right) the injection of 20-nm PHEA-C16-iron oxide nanoparticles.
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no precipitation of the PHEA-C16-iron oxide in the top
agar. There was neither significant increase nor growth
inhibition of colony in all PHEA-C16-iron oxide-treated
plates in all strains. In all positive control groups, posi-
tive response was obtained. It was concluded that the
PHEA-C16-iron oxide was not able to induce reverse
mutation in the tester strains used in this study.
In vitro mammalian chromosome aberration test of PHEA-
C16-iron oxide in cultured Chinese hamster lung cells
There were no statistically significant increases in the
frequencies of aberrant metaphases with structural or
numerical aberrations in the PHEA-C16-iron oxide-
treated groups compared with the corresponding nega-
tive control groups. In the positive control groupsFigure 6 Prussian blue staining. Prussian blue-stained iron taken up by t
oxide. Lymph node at × 200 (left) and × 400 magnifications.treated with benzo[a]pyrene (+S) or ethylmethanesulfo-
nate (−S), positive responses were observed. Therefore,
it was concluded that PHEA-C16-iron oxide did not in-
duce chromosomal aberrations in the CHL cells which
were used in this study.
Discussion
In this study, we have prepared biocompatible PHEA-
C16-iron oxide nanoparticles with sizes of 20, 70, and
150 nm, controlled by the amount of C16 as a hydropho-
bic side chain. In vitro and in vivo experiments were per-
formed with 20-nm particles; USPIO was used because
the purpose of this study was to develop a novel MRI
contrast agent for the detection of lymph nodes. The
PHEA-C16-iron oxide as compared with Resovist®, a clin-
ically approved MRI contrast agent, showed slightlyhe lymph node of a rabbit after injection of 20-nm PHEA-C16-iron
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from the in vitro phantom test. The PHEA-C16-iron
oxide could also effectively detect bone marrow and
lymph node of the rabbit by MRI. A single-dose intra-
venous toxicity and gene toxicity study of the PHEA-
C16-iron oxide was commissioned by the preclinical re-
search center of ChemOn, Inc. The results of LD50 from
single-dose toxicity test were calculated 1,500 mg/kg for
males and 1,300 mg/kg for females. PHEA-C16-iron
oxide was confirmed biocompatible and nontoxic be-
cause genetic toxicity tests show negative results. These
results indicate the great potential applications of
PHEA-C16-iron oxide for the detection of lymph nodes
by MRI.
Conclusions
The results suggest that the PHEA-C16-iron oxide has
slightly better imaging contrast effect than the clinically
approved contrast agent Resovist®. The PHEA-C16-iron
oxide has excellent imaging contrast in the liver, blood
vessel, and even in the lymph node. With its biocompat-
ible and nontoxic characteristics, the PHEA-C16-iron
oxide is a promising candidate for a new contrast agent.
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